Direct medical cost of managing deep vein thrombosis according to the occurrence of complications

JA O'Brien, JJ Caro - Pharmacoeconomics, 2002 - Springer
Background: Management of deep vein thrombosis (DVT) has evolved from hospitalisation
for intravenous heparin therapy to treatment options that include acute management as an …

The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy

MA Rodger, C Gagné-Rodger, HE Howley, M Carrier… - Thrombosis research, 2003 - Elsevier
Background: The outpatient treatment of deep vein thrombosis (DVT) with low-molecular-
weight heparin (LMWH) has been shown to be cost-effective from the perspective of a third …

Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care center: a cost‐minimization analysis

M Boucher, M Rodger, JA Johnson… - … : The Journal of …, 2003 - Wiley Online Library
Study Objective. To compare the cost of contemporary outpatient and historical inpatient
management of proximal lower limb deep vein thrombosis (DVT) in adults. Design …

Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program.

JB Groce 3rd - Pharmacotherapy, 1998 - europepmc.org
Low-molecular-weight heparins are safe and effective for outpatient treatment of deep vein
thrombosis (DVT). An outpatient DVT treatment program was established in a 532-bed …

Deep venous thrombosis: a new task for primary health care A randomised economic study of outpatient and inpatient treatment

K Bäckman, P Carlsson, M Kentson… - … journal of primary …, 2004 - Taylor & Francis
Objective A health economic evaluation of two alternative treatment settings, inpatient care
and outpatient care, for acute deep venous thrombosis. Design A randomised multicentre …

Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis

CA Estrada, CJ Mansfield, GR Heudebert - Journal of general internal …, 2000 - Springer
OBJECTIVE: To estimate the cost-effectiveness of low-molecular-weight heparin (LMWH) in
the treatment of proximal lower extremity deep venous thrombosis. DESIGN: Cost …

Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis

JJ Caro, D Getsios, I Caro, JA O'Brien - Pharmacoeconomics, 2002 - Springer
Objective: To evaluate economic and health implications of tinzaparin sodium, a once a day
low-molecular-weight heparin (LMWH), versus unfractionated heparin (UFH) in the …

[HTML][HTML] Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation

R Guanella, T Ducruet, M Johri, MJ MIRON… - Journal of Thrombosis …, 2011 - Elsevier
Background: Few studies have evaluated the long‐term economic consequences of deep
vein thrombosis (DVT). None of them have incorporated prospectively collected clinical data …

The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects

RD Hull, GF Pineo, GE Raskob - Pathophysiology of Haemostasis and …, 1998 - karger.com
Subcutaneous low-molecular-weight heparin (LMWH) is at least as safe and effective as
classical intravenous heparin therapy for the treatment of proximal vein thrombosis …

Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital

M Lee, D Pao, T Hsu, A Sonderskov - Journal of Population …, 2004 - jptcp.com
This study was conducted at Centenary Health Centre of the Rouge Valley Health System, a
community based hospital in Toronto. In January 1997, a new treatment was introduced for …